Black Diamond Therapeutics, Inc.
25 Health Sciences Drive
4 articles with Black Diamond Therapeutics, Inc.
Team also strengthened with key hires in preclinical and clinical development, clinical operations, and finance to drive company's lead program into the clinic in 2020 and advance its pipeline and MAP platform
Black Diamond Therapeutics Presents Data From its Program Targeting Oncogenic Allosteric Mutations in EGFR for Glioblastoma as Late Breaker at the American Association for Cancer Research (AACR) Annual Meeting
Black Diamond Therapeutics, Inc. announced that data from its first-in-class program targeting a group of epidermal growth factor receptor allosteric mutants that drive glioblastoma multiforme will be presented at the American Association for Cancer Research Annual Meeting 2019.
Next-wave precision oncology company poised to advance multiple products into clinical development
Next-wave precision oncology company emerges from Versant’s Ridgeline Discovery Engine